Phase II Study Comparing In-Person Physician Monitoring Versus Remote Nurse Monitoring for Personalized Post-Treatment Surveillance in Adults With Rare Tumors

What this Trial Is About

Researchers are evaluating compliance with personalized post-treatment surveillance plans in adults recently diagnosed within 12 months with rare tumors. This multicenter, randomized study compares monitoring conducted in person by a hospital-based physician versus remote monitoring by a trained nurse. The study aims to understand how these two approaches affect patient adherence to follow-up care and overall management of their condition. Participants are randomly assigned to one of two groups. One group receives post-cancer surveillance, including biological, clinical, and imaging exams, conducted remotely by a nurse. The other group undergoes on-site surveillance by a hospital physician. The study includes a 2-year primary evaluation period, with extended follow-up planned for up to 5 years to assess long-term compliance, use of care, oncological events, and supportive care needs. Additional exploratory goals include evaluating transportation costs and patient satisfaction. During the study, participants will be regularly monitored according to their personalized surveillance plan, with assessments of compliance tracked over 2 and 5 years. Researchers will measure outcomes such as progression-free and overall survival, dropout rates, and psychological well-being related to anxiety and depression. The study also examines the impact of factors like gender, tumor type, occupational status, and treatment center on results. This comprehensive follow-up aims to provide detailed information on the feasibility and effects of remote versus in-person monitoring.

Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring